Title:
REGENERATIVE AGENT FOR BONE TISSUE AND LUNG TISSUE, AND PHARMACEUTICAL COMPOSITION FOR REGENERATING BONE TISSUE AND LUNG TISSUE
Document Type and Number:
WIPO Patent Application WO/2023/048125
Kind Code:
A1
Abstract:
A regenerative agent for bone tissue and lung tissue that contains a macrolide antimicrobial agent as an active ingredient. The macrolide antimicrobial agent may be one or more selected from the group consisting of erythromycin, azithromycin and clarithromycin. The regenerative agent for bone tissue and lung tissue may be topically administered to a bone tissue or a lung tissue. A pharmaceutical composition for regenerating bone tissue and lung tissue that comprises the aforesaid regenerative agent for bone tissue and lung tissue and a pharmaceutically acceptable carrier.
Inventors:
MAEKAWA TOMOKI (JP)
TABETA KOICHI (JP)
TERAO YUTAKA (JP)
TAMURA HIKARU (JP)
TABETA KOICHI (JP)
TERAO YUTAKA (JP)
TAMURA HIKARU (JP)
Application Number:
PCT/JP2022/034943
Publication Date:
March 30, 2023
Filing Date:
September 20, 2022
Export Citation:
Assignee:
UNIV NIIGATA (JP)
International Classes:
A61K45/00; A61K31/7048; A61K31/7052; A61P1/02; A61P11/00; A61P19/00; A61P19/02; A61P19/10; A61P29/00; A61P31/04
Domestic Patent References:
| WO2006137423A1 | 2006-12-28 |
Foreign References:
| JP2021156321A | 2021-10-07 |
Other References:
TOMOKI MAEKAWA: "JR-2: Elucidation of anti-inflammatory mechanism of erythromycin via DEL-1", JOURNAL OF ORAL BIOSCIENCES, vol. 63, no. Suppl., 22 September 2021 (2021-09-22), pages 36, XP009544759, ISSN: 1349-0079
TOMOKI MAEKAWA: "Bone metabolism control by DEL-1 molecular regulation and development to anti-aging", PRECISION MEDICINE, vol. 4, no. 5, 25 May 2021 (2021-05-25), pages 495 - 499, XP009544760, ISSN: 2434-3625
MAEKAWA TOMOKI, TAMURA HIKARU, DOMON HISANORI, HIYOSHI TAKUMI, ISONO TOSHIHITO, YONEZAWA DAISUKE, HAYASHI NAOKI, TAKAHASHI NAOKI, : "Erythromycin inhibits neutrophilic inflammation and mucosal disease by upregulating DEL-1", JCI INSIGHT, vol. 5, no. 15, 6 August 2020 (2020-08-06), XP093052062, DOI: 10.1172/jci.insight.136706
MAEKAWA T ET AL.: "Erythromycin inhibits neutrophilic inflammation and mucosal disease by upregulating DEL-1.", JCI INSIGHT, vol. Vol. 5, 2020, pages e136706
MAEKAWA T ET AL.: "Antagonistic effects of IL-17 and D-resolvins on endothelial Del-1 expression through a GSK-3(3-C/EBP(3 pathway.", NATURE COMMUNICATIONS, vol. 6, no. 8272
ZIOGAS A ET AL.: "DHEA Inhibits Leukocyte Recruitment through Regulation of the Integrin Antagonist DEL-1.", J IMMUNOL, vol. 204, no. 5, 2020, pages 1214 - 1224
ESKAN MA ET AL.: "The leukocyte integrin antagonist Del-1 inhibits IL-17-mediated inflammatory bone loss.", NATURE IMMUNOLOGY, vol. 13, no. 5, 2012, pages 465 - 473, XP055672883, DOI: 10.1038/ni.2260
SHIN J ET AL.: "DEL-1 restrains osteoclastogenesis and inhibits inflammatory bone loss in nonhuman primates.", SCIENCE TRANSLATIONAL MEDICINE, vol. 7, no. 307, 2015, pages 307ra155, XP055672885, DOI: 10.1126/scitranslmed.aac5380
MITROULIS I ET AL.: "Secreted protein Del-1 regulates myelopoiesis in the hematopoietic stem cell niche.", J CLIN INVEST, vol. 127, no. 10, 2017, pages 3624 - 3639
TOMOKI MAEKAWA: "Bone metabolism control by DEL-1 molecular regulation and development to anti-aging", PRECISION MEDICINE, vol. 4, no. 5, 25 May 2021 (2021-05-25), pages 495 - 499, XP009544760, ISSN: 2434-3625
MAEKAWA TOMOKI, TAMURA HIKARU, DOMON HISANORI, HIYOSHI TAKUMI, ISONO TOSHIHITO, YONEZAWA DAISUKE, HAYASHI NAOKI, TAKAHASHI NAOKI, : "Erythromycin inhibits neutrophilic inflammation and mucosal disease by upregulating DEL-1", JCI INSIGHT, vol. 5, no. 15, 6 August 2020 (2020-08-06), XP093052062, DOI: 10.1172/jci.insight.136706
MAEKAWA T ET AL.: "Erythromycin inhibits neutrophilic inflammation and mucosal disease by upregulating DEL-1.", JCI INSIGHT, vol. Vol. 5, 2020, pages e136706
MAEKAWA T ET AL.: "Antagonistic effects of IL-17 and D-resolvins on endothelial Del-1 expression through a GSK-3(3-C/EBP(3 pathway.", NATURE COMMUNICATIONS, vol. 6, no. 8272
ZIOGAS A ET AL.: "DHEA Inhibits Leukocyte Recruitment through Regulation of the Integrin Antagonist DEL-1.", J IMMUNOL, vol. 204, no. 5, 2020, pages 1214 - 1224
ESKAN MA ET AL.: "The leukocyte integrin antagonist Del-1 inhibits IL-17-mediated inflammatory bone loss.", NATURE IMMUNOLOGY, vol. 13, no. 5, 2012, pages 465 - 473, XP055672883, DOI: 10.1038/ni.2260
SHIN J ET AL.: "DEL-1 restrains osteoclastogenesis and inhibits inflammatory bone loss in nonhuman primates.", SCIENCE TRANSLATIONAL MEDICINE, vol. 7, no. 307, 2015, pages 307ra155, XP055672885, DOI: 10.1126/scitranslmed.aac5380
MITROULIS I ET AL.: "Secreted protein Del-1 regulates myelopoiesis in the hematopoietic stem cell niche.", J CLIN INVEST, vol. 127, no. 10, 2017, pages 3624 - 3639
Attorney, Agent or Firm:
TAZAKI Akira et al. (JP)
Download PDF: